SFP
ALNY icon

Santa Fe Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Santa Fe Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-25,658
Closed -$2.68M – 473
2015
Q1 		$2.68M Buy
+25,658
New +$2.6M 0.32% 102
2014
Q4 		– Sell
-14,374
Closed -$1.12M – 481
2014
Q3 		$1.12M Buy
+14,374
New +$927K 0.17% 235

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Santa Fe Partners's ALNY Position: Q2 2015 in Review

Santa Fe Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2015, closing a stake of 25,658 shares — an estimated $2.68M sold.

Santa Fe Partners first reported a position in ALNY in Q3 2014 and held it in 2 quarters. The position peaked at $2.68M in Q1 2015. 278 funds tracked by Wall St. Rank hold ALNY as of Q2 2015.

  • Santa Fe Partners reported no remaining Alnylam Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Santa Fe Partners sold 25,658 Alnylam Pharmaceuticals shares in Q2 2015, an estimated $2.68M.
  • Santa Fe Partners first reported a position in Alnylam Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Santa Fe Partners's Alnylam Pharmaceuticals position peaked at $2.68M in Q1 2015.
  • 278 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2015.

Based on Santa Fe Partners's 13F filing for Q2 2015, filed 13 Aug 2015.